Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients.

ABSTRACT:

Purpose

To investigate the value of performing mid-treatment axillary ultrasound (AUS) in triple-negative breast cancer (TNBC) patients who are undergoing neoadjuvant systemic therapy (NAST) by determining the optimal cutoff number of abnormal nodes associated with residual nodal disease on surgical pathology.

Materials and methods

This sub-study, an interim analysis of an ongoing single-institution clinical trial enrolling patients with stage I-III TNBC, included 106 patients. Number of abnormal nodes at mid-treatment was assessed and recorded by experienced breast radiologists, who empirically categorized lymph nodes using a binary approach of sonographically-normal versus abnormal. Pathologic lymph node positivity was defined as presence of macrometastasis or micrometasta

SUBMITTER: Candelaria RP 

PROVIDER: S-EPMC7534548 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature